In amyotrophic lateral sclerosis (ALS), nerve cells in the spinal cord responsible for inhibiting motor neurons are lost in the early stages of the disease, before the motor neurons themselves, according to a new study done in a genetic mouse model of ALS. The researchers also found that excitatory…
News
Treatment with fasudil (RT1968), which Raya Therapeutic is testing for amyotrophic lateral sclerosis (ALS), was safe and outperformed a placebo at preserving motor neurons in adults with early-stage disease. That’s according to data from ROCK-ALS (NCT03792490), an investigator-led Phase 2a trial that tested how safe fasudil is…
The use of nonpharmacological treatment — interventions such as muscle exercise, aerobics, and strength training — did not significantly ease pain among people with amyotrophic lateral sclerosis (ALS), according to a review of published data from five clinical trials. The researchers noted, however, that while “pain in ALS patients…
The ALS Association is commending the National Academies of Sciences, Engineering, and Medicine for its “groundbreaking” and comprehensive report that maps a way toward making amyotrophic lateral sclerosis (ALS) a livable disease within a decade. The organization and ALS advocates played a key role in pushing for…
Bravyl, an investigational oral therapy from Woolsey Pharmaceuticals, was safe and lowered levels of the nerve damage biomarker neurofilament light chain (NfL) in people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2a clinical trial. The medication also showed early signs of slowing disease…
Athira Pharma has completed enrollment of the first group of healthy volunteers who’ll receive a single dose of ATH-1105, its experimental oral therapy for amyotrophic lateral sclerosis (ALS), in a Phase 1 clinical trial. The Phase 1 trial (NCT 06432647),…
After up to 3.5 years on the experimental oral treatment CNM-Au8, the chances of survival for people with amyotrophic lateral sclerosis (ALS) in the open-label extension of the HEALEY ALS platform trial was nearly 60% higher than for a group of patients given a placebo in previous studies.
Adding Radicava (edaravone) to riluzole prolongs survival of amyotrophic lateral sclerosis (ALS) patients by more than three months relative to riluzole alone, according to analyses of real-world data from the ALS/MND Natural History Study Consortium database. These and other Radicava-related findings were presented by the therapy’s developer…
COYA 302, Coya Therapeutics’ experimental immune-modulating combination therapy, safely slows disease progression and reduces levels of disease biomarkers in people with amyotrophic lateral sclerosis (ALS). That’s according to the now-published results from a small proof-of-concept Phase 1 clinical trial (NCT06307301) that tested the therapy in four ALS…
People with amyotrophic lateral sclerosis (ALS) who are treated by a neurologist are more likely to receive evidence-based care endorsed by the American Academy of Neurology than those who see non-neurologist providers, according to an analysis of Medicare data. Still, fewer than half of the ALS patients studied…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients